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Abstract: The test methods that currently exist for the identification of thyroid hormone
system-disrupting chemicals are woefully inadequate. There are currently no internationally validated
in vitro assays, and test methods that can capture the consequences of diminished or enhanced
thyroid hormone action on the developing brain are missing entirely. These gaps put the public
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at risk and risk assessors in a difficult position. Decisions about the status of chemicals as thyroid
hormone system disruptors currently are based on inadequate toxicity data. The ATHENA project
(Assays for the identification of Thyroid Hormone axis-disrupting chemicals: Elaborating Novel
Assessment strategies) has been conceived to address these gaps. The project will develop new
test methods for the disruption of thyroid hormone transport across biological barriers such as
the blood–brain and blood–placenta barriers. It will also devise methods for the disruption of the
downstream effects on the brain. ATHENA will deliver a testing strategy based on those elements of
the thyroid hormone system that, when disrupted, could have the greatest impact on diminished
or enhanced thyroid hormone action and therefore should be targeted through effective testing.
To further enhance the impact of the ATHENA test method developments, the project will develop
concepts for better international collaboration and development in the area of thyroid hormone
system disruptor identification and regulation.
Keywords: endocrine disruptors; thyroid hormone system; brain development; test method
development; test method validation; risk assessment
1. Introduction
The development of internationally validated test methods for chemicals that disrupt the thyroid
hormone system has not kept pace with the scientific advances in the field of thyroid hormone (TH)
endocrinology and physiology. As a result, we are not protected against “surprises” from chemicals
that suddenly reveal their potential as TH system disruptors with adverse consequences for brain
development in foetal and neonatal life.
A major weakness of the currently validated test methods is the lack of assays specific to the
impairment of brain development. This puts risk assessors in a difficult position: unable to base
their evaluations on relevant brain-related endpoints, the danger of developmental neurotoxicity
must be inferred from data related to histopathological changes in the thyroid gland or TH serum
concentrations, which are taken as evidence of the disruption of the thyroid hormone system. Whether
or not this also leads to developmental neurotoxicity is often unclear, especially in cases when the
concentrations of circulating thyroid hormones are perturbed, but without histological changes in the
thyroid [1].
The ATHENA consortium, funded by the European Union (EU) Horizon 2020 programme, aims to
close this disturbing gap by mobilizing the scientific progress made in recent years regarding our
understanding of the TH system. We focus on TH system disruption that arises from interference
with TH transport processes to the foetus, from disturbances of the cellular uptake and intra-cellular
deiodination of TH and from disruptions of the local control of the receptor-mediated action of TH in
target cells. We will establish new toxicity endpoints that will allow us to capture the downstream
effects of TH system disruption on the developing brain in foetal and post-natal life.
THs play essential roles in growth and development by controlling cell differentiation, migration
and homeostasis. Hormone synthesis is regulated by the hypothalamic–pituitary–thyroid axis. Effective
tissue levels of THs are controlled through multiple layers of regulation including deiodinations in
peripheral tissues, specific cell membrane transporters, binding to distributor proteins, the removal of
TH by sulfation or glucuronidation in the liver, or the modulation of iodide uptake into the thyroid
(Figure 1) [2]. All these mechanisms influence the availability of THs in the receptors inside target cells.
This complex regulatory system can be disrupted at multiple levels—for example, by chemicals that
suppress TH synthesis, interfere with the uptake of iodide into the thyroid gland, block the transfer of
THs across physiological barriers or stimulate the clearance of THs in the liver [2].
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Figure 1. The thyroid hormone system and its regulation. (adapted and modified from Gilbert et al. 
(2012) [2]). Abbreviations are listed at the end of the paper. 
In humans, both too low and too high serum TH availability are associated with negative health 
impacts [3]. Non-optimal thyroid hormone availability during pregnancy has been associated not 
only with suboptimal child neurocognitive and brain morphological outcomes, but also pre-
eclampsia, intrauterine growth restriction and preterm birth. Outside of pregnancy, non-optimal TH 
availability is associated with a higher risk of cardiovascular disease, cardiac arrhythmias, 
osteoporosis and the disturbance of lipid metabolism. For this reason, the ATHENA project will focus 
on pre-receptor TH regulatory mechanisms that lead to TH system disruption. We will develop test 
methods that can capture adverse outcomes on the developing brain. The project will be completed 
at the end of 2023. 
In this article, we describe the concept and approaches of the ATHENA project [4], give an 
overview of some first achievements and discuss the relevance of ATHENA in the context of the 
international regulatory landscape. ATHENA is part of the European Cluster to Improve 
Identification of Endocrine Disruptors (EURION, https://eurion-cluster.org), which is composed of 
eight EU-funded projects which collaborate on test method development. 
2. Results 
2.1. Terminology, Concept and Rationale 
There are ambiguities in the naming of chemicals that can disrupt the functions of the TH system. 
Frequently, these are referred to as “thyroid disruptors”, but this is sometimes taken to apply only to 
chemicals that disrupt the thyroid gland directly. Interference with other aspects of the TH system, 
such as effects on serum distributor proteins, cell membrane transporters, intracellular deiodinases 
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In humans, both too low and too high serum TH availability are associated with negative health
impacts [3]. Non-optimal thyroid hormone availability during pregnancy has been associated not
only with suboptimal child neurocognitive and brain morphological outcomes, but also pre-eclampsia,
intrauterine growth restriction and preterm birth. Outside of pregnancy, non-optimal TH availability
is associated with a higher risk of cardiovascular disease, cardiac arrhythmias, osteoporosis and the
disturbance of lipid metabolism. For this reason, the ATHENA project will focus on pre-receptor TH
regulatory mechanisms that lead to TH system disruption. We will develop test methods that can
capture adverse outcomes on the developing brain. The project will be completed at the end of 2023.
In this article, we describe the concept and approaches of the ATHENA project [4], give an
overview of some first achievements and discuss the relevance of ATHENA in the context of the
international regulatory landscape. ATHENA is part of the European Cluster to Improve Identification
of Endocrine Disruptors (EURION, https://eurion-cluster.org), which is composed of eight EU-funded
projects which collaborate on test method development.
2. Results
2.1. Terminology, Concept and Rationale
There are ambiguities in the naming of chemicals that can disrupt the functions of the TH system.
Frequently, these are referred to as “thyroid disruptors”, but this is sometimes taken to apply only to
chemicals that disrupt th thyroid gla d directly. Interference with other aspects of the TH syste ,
such as effec s on serum distributor proteins, cell membrane ransporters, intracellular deiodinases
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(DIO) or liver-conjugating enzyme systems for the elimination of TH, to name a few, are then not
taken into account and referred to as merely “indirect” effects. However, disturbances of any of these
aspects can also lead to adverse effects. To express this insight, we avoid the term “thyroid disruptor”
throughout this article. Instead, we use the term “TH system disruptors” to refer to substances with the
ability of disrupting any aspect of the TH system. Accordingly, the process itself is called “TH system
disruption”.
The ATHENA concept for advancing improved and novel test methods for the detection of TH
system disruptors provides enhancements on several levels:
• The development of quantitative structure–activity relationships (QSARs) for molecular initiating
events leading to diminished TH action, to allow for the improved screening of candidate TH
system disruptors;
• The scaling up of in vitro methods for the inhibition of deiodinases, dehalogenases and cell
membrane TH transporters to a high throughput format;
• The development of new assays to capture the disruption of the delivery of THs across physiological
barriers (cell membrane transporters in the blood–brain barrier, the blood–cerebrospinal fluid
barrier, and the placenta);
• The development of new assays based on human pluripotent stem cell-derived brain cells and
brain organoids to complement and, to a certain extent, replace current animal models;
• The identification of endpoints reflective of brain morphology and markers of brain development
for possible inclusion in existing Organisation for Economic Co-operation and Development
(OECD) test guidelines;
• The integration of new and existing test methods into a coherent testing strategy;
• The validation of the human relevance of new test methods.
The realisation of some of these aspects will require basic research, while others can build on
existing assays that need further refinement to reach the pre-validation stage. There is an urgent need
to integrate test methods by elaborating coherent testing strategies that can support effective hazard
characterisations and regulatory decisions. These testing strategies will specify sequential deployments
of tests to comprehensively capture all aspects of TH system disruption. There is also the need for
international harmonisation of hazard characterisations for TH system disruptors.
2.2. Regulatory and Societal Needs for New Test Methods for Thyroid Hormone System Disruption
The need to identify the TH system-disrupting potential of chemicals derives from EU legal
requirements for the protection against endocrine-disrupting chemicals expressed in various EU
chemicals regulations (e.g., Biocidal Products Regulation (EU) No 528/2012, Plant Protection
Products Regulation (European Commission) No 1107/2009, Regulation on Registration, Evaluation,
Authorisation and Restriction of Chemicals (REACH; European Commission 1907/2006)). It is widely
acknowledged that the internationally validated and accepted OECD test methods for endocrine
disruptors are inadequate for the identification of TH system-disrupting chemicals [1]. Therefore,
the legal mandate for protection against endocrine disruptors and TH system disruptors cannot
currently be fully realised.
Although in vitro methods that capture various aspects of TH synthesis, transport and
metabolism [5] have been available for a considerable period, none of these methods are validated
internationally and therefore are not used for regulatory testing. As a result, there is currently not
a single in vitro method for TH system disruptors implemented in Level 2 of the OECD Conceptual
Framework for endocrine disruptor testing [1]. Similarly, Level 3 (in vivo assays providing data
about selected endocrine mechanisms) does not specify any thyroid-related endpoints. Moreover,
the Level 4 test guideline (TG) 407 (repeated dose 28-day study, adult animals) only includes
thyroid gland histopathology, with optional TH measurements. An update of TG 408 (repeated
dose 90-day oral toxicity) includes mandatory TH measurements. In recent years, some Level 4
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tests (reproductive toxicity screening and developmental toxicity) have been amended to include TH
measurements in some of the animals. At Level 5 of the OECD Conceptual Framework, only the
Extended One-Generation Reproductive Toxicity Study (EOGRTS, TG 443) includes mandatory TH
measurements, but downstream effects of diminished TH action on the brain are insufficiently
covered and poorly developed. The currently available neuro-behavioural tests used to capture
this kind of developmental neurotoxicity are rarely included in regulatory testing studies. As a
result, most chemicals have not been tested for potential developmental neurotoxicity. In any case,
the available neuro-behavioural tests are normally not sufficiently sensitive for the reliable detection of
TH system disruptors.
The lack of adequate test methods severely constrains the evaluation of chemicals as TH system
disruptors. The absence of reliable downstream effect markers for disturbance of brain development
and the deficiencies of in vitro methods mean that chemicals have to be assessed mainly on the basis of
their capability of inducing histopathological changes in the thyroid and in terms of their ability to
alter TH serum levels. However, modulations of hormone levels alone give an inadequate reflection of
a chemical’s ability to disrupt the TH system. Furthermore, the thyroid is not the only target organ
of the TH system. The result is that the TH system-disrupting properties of many chemicals are
insufficiently identified or even entirely overlooked, especially in relation to the disruption of foetal
brain development.
Furthermore, coherent testing strategies for the identification of TH system-disrupting chemicals
are missing altogether. It can be anticipated that exposures that limit the synthesis of THs by restricting
the uptake of iodide into the thyroid gland, or by blocking hormone-synthesising enzymes, will have
a strong impact on TH action. It remains to be seen whether a testing strategy should begin with
in vitro assays for uptake inhibition, or the inhibition of hormone synthesis, or whether other molecular
initiating events should also be considered. It is further necessary to elaborate which tests should be
deployed in the case of positive outcomes of initial in vitro tests, and when the scene might be set to
proceed to testing with cost-intensive multi-generation in vivo mammalian assays.
2.3. Overall Approach and Methodology
The ATHENA project is organised into four project domains:
• Domain 1: Mobilising basic research for the development of novel assays for TH system disruption;
• Domain 2: The development of test methods towards assay pre-validation and ring-testing;
• Domain 3: Testing strategies and testing in a multi-causal context;
• Domain 4: Enhanced international collaboration and development of international strategies for
TH system disruptor identification and regulation.
2.3.1. Domain 1: Mobilising Basic Research for the Development of Novel TH System
Disruption Assays
In this domain, we conduct basic research that can orient and underpin the development of test
methods in domain 2 of the project, in terms of aspects of the TH system that need to be addressed
by test methods, the selection of test chemicals, as well as features of human physiology not readily
re-capitulated in experimental studies and in vitro and in vivo test methods.
We are leveraging human epidemiological data to guide the decision-making process for
test method development and test compound selection. We are interrogating data from several
epidemiological cohorts to take stock of the known associations of chemical exposures with adverse
health outcomes related to maternal thyroid function. This will provide a basis for the selection of test
chemicals and components of the TH system that should be the initial targets when setting up assay
development. We have identified the associations of several endocrine-disrupting chemicals with
disruptions of maternal thyroid function using epidemiological data from the Swedish Environmental
Longitudinal, Mother and child, Asthma and allergy (SELMA) cohort and the Generation R
study [6]. To complement our work, we will also use experimental data with newly discovered TH
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system-disrupting chemicals to probe possible exposure effect associations in human epidemiological
data. We have successfully used human epidemiological data to elucidate TH system-disrupting effects
that are specific to human pregnancy physiology and which cannot be examined in experimental
systems [6].
We are screening for candidate TH system disruptors by developing advanced QSAR models.
This work builds up valuable criteria for test chemical selection from a molecular/mechanistic
perspective. We are developing new QSARs for the inhibition of deiodinases, dehalogenase and TH
membrane transporters in order to screen REACH chemicals, pesticides, biocides and pharmaceuticals
for their potential to disrupt components of the TH system. The results from the high throughput
assays to be developed and refined in domain 2 of ATHENA (see below) will produce comprehensive
datasets, which will be used to design and refine complex and well-trained QSAR algorithms that can
characterise chemicals as potential TH system disruptors (Figure 2).
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of neural cell fate decisions by using two models, (i) hu an brain organoids a d (ii) eurospheres
established from the ubventricular zone of postn tal and adult mice (Figure 3). We have also derived
brain organoids that were generated from human-induced pluripotent stem cells [7]. Thes sy s will
help us to establish how TH sy tem-disrupting chemical can interfere wit bra n development, neural
stem cell differentia io and key processes during foetal brain development. These hi hly promising
no a proaches mimic t e complex three-dimensional intercellular communication between different
types of brain cells (e.g., neurons, oligodendrocytes, astrocytes). These assays will undergo technical
refinem nt and optimisation in an iterative process of broad applications, the goal b ing to reduce,
refine nd replace animal experiments (3R) and to crease the throughput capacity of in vitro and
ex vivo test methods. This research will provide the basis for n vel in vitro/ex vivo test methods
and links directly w h the in ivo udies f thyroid hormone do nstream effects on th developing
brain undertaken in domain 2. Together with these in vivo test metho s, the work wit human brain
organ id and mouse neurospheres will provide a compelli g platform for examining the impact
of the d sru tion of TH transport into brain cells an the impact of the i terfere ce with local TH
activations r inactivations on cell fate decisions.
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2.3.2. Domain 2: Development of Test ethods towards Assay Pre-Validation and Ring-Testing
In this domain, we are conducting the research and method optimisations required to take existing
TH system disruptor assays from the pilot and research stages to the test method pre-validation
stage. We are carrying out thorough assessments in terms of assay reliability, sensitivity, efficiency
and technical feasibility at a high throughput screening (HTS) level, based on rigorous statistical and
biometrical analyses. This work incorporates all aspects important to the international validation
process in the OECD Test Guideline Framework. The work in domain 2 probes the TH system with
a focus on TH metabolism (deiodination, dehalogenation), transport processes across physiological
barriers and downstream effects on the developing foetal brain. Our work complements the efforts
currently undertaken in the Network of Laboratories for the Validation of Alternative Methods
(NETVAL) process coordinated by the European Commission’s Joint Research Centre.
We are developing high throughput screening (HTS) for specific inhibitors of iodothyronine
deiodinase 2 & 3, iodotyrosine dehalogenase 1 (IYD) and TH transporter organic anion transporter
1c1 (OATP1C1) to generate QSAR training sets and reference compound libraries. This builds on
established assay protocols, developed by ATHENA partners. These protocols utilise a convenient
colorimetric, non-radioactive method for the detection of iodine based on the Sandell–Kolthoff reaction.
A panel of recently developed assays [8] is scaled up to a new level of throughput and superior quality.
These will be optimised for a high throughput format (384-well plate) and semi-automated handling.
We will deliver a common assay platform in which distinct DIOs, IYDs, and recently discovered cell
membrane TH transporters can be tested. A key benefit of this work will be its transferable and
high-quality protocols, which will be ready for validation and adoption by user labs. We ill perform
the screening of large compound libraries, consisting of a diverse set of orphan molecules, including
pre-selected REACH chemicals. This screening will deliver training sets for QSAR development and
refinement in domain 1. Conversely, we will verify experimentally QSAR-predicted active REACH
chemicals. The screening effort will also generate a valuable library of specific and selective inhibitors
of deiodinases, dehalogenases and membrane transporters. We will use this library in other in vivo
and ex vivo assays to establish the outcomes and biomarkers that result from these specific modes of
action of disrupting the TH system.
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We are analysing the disruption of TH transport across physiological barriers and are scaling up
existing cell models genetically engineered to overexpress the established transporters monocarboxylate
transporter (MCT 8/10) and OATP1C1 for high throughput assays. We utilise non-radioactive
iodine detection methods (Sandell–Kolthoff reaction). The aim is to deliver HTS protocols ready
for pre-validation via the extension and refinement of existing protocols [9]. We will conduct basic
research on identifying the main TH transporters in the placenta, the blood–brain barrier and the
blood–cerebrospinal fluid barrier by using established polarised cell models in trans-well cultures
and by using perfused placenta models. Newly identified, novel transporters are overexpressed in
established cell lines and the resulting genetically engineered cell lines are further developed into high
throughput assays for the identification of chemicals capable of disrupting TH transporters. This work
will be complemented and expanded by studying the role of the distributor protein transthyretin (TTR)
in TH transport across the polarised cell models, representing the placenta and the blood–cerebrospinal
fluid barrier. TTR is the main TH binding protein in the cerebrospinal fluid and is directionally secreted
from choroid plexus epithelial cells, which form these barriers, into the cerebrospinal fluid. Similarly,
TTR is directionally secreted by placental cells into the foetal environment, where it represents the
relevant TH-binding protein. Recently, we have assessed the impact of mixtures of chemicals on
displacing THs from TTR in serum [10].
We have explored the feasibility of using endpoints reflective of disruptions of differentiation,
maturation and migration of brain cells during the development of in vivo assays for the downstream
effects on brain development in mammals. We use exposure schedules and formats resembling
those used in OECD test guidelines (TG) for developmental neurotoxicity studies and the Extended
One-Generation Reproductive Toxicity Study (EOGRTS; OECD TG 426, TG 443) in rodents. We explore
the utility of various methods for the characterisation of brain morphology. We are specifically
evaluating the formation of heterotopias, misplaced neurons in the corpus callosum that occur after
severe TH deficiency during development. This lesion is the result of the disrupted migration of
neuronal cells to the brain cortex. The team around Mary Gilbert at the United States Environmental
Protection Agency (US EPA) [11] discovered this form of brain damage after exposing rats to inhibitors
of thyroid peroxidase, a key enzyme in the synthesis of THs. We have successfully adopted this
method and are ready to test chemicals for their ability to produce this damage to the developing brain
(Figure 4).
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appearance of the corpus callosum in a control rat. Panel (b), right, shows heterotopia in the corpus
callosum of a rat exposed in foetal life and postnatally to propylthiouracil (maternal dose: 2.5 mg/kg d).
The arrows point to the misplaced cells. Scale bars: 1 cm.
We are investigating whether similar lesions also occur in the mouse. This will enable us to
pinpoint features of the TH system that will impact on species–species sensitivity differences and will
help us to assess the human relevance of the rodent models. We also focus on disruptions of cell
differentiation and migration, as they materialise in terms of changes in gene expression, cerebellar
histogenesis, the altered ratio of neurons vs. glial cells and misplaced neurons left behind during
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disrupted cell migration. We further evaluate serum TH levels (TSH, T4, T3) and effects on the liver
(the main TH metabolising organ) by analysing hepatic gene expression. Ex vivo analyses of the
thyroid will enable us to establish several functional readouts, including gene expression profiles,
iodine content, deiodinase and dehalogenase activities, based on the non-radioactive Sandell–Kolthoff
assay platforms. In this way, we hope to integrate the possible interference of test chemicals at the
sites of thyroid hormone synthesis (the thyroid), metabolism and elimination (the liver) and a primary
target of TH action during development (the brain).
By robotising the Xenopus Eleutheroembryonic Thyroid Assay (XETA), we build on the existing
XETA assay, which has been validated in international ring tests [12]. We are scaling up this test
method to enable high throughput testing by robotisation and to develop additional endpoints to make
the XETA experiments more informative for assessing the mode of action of the substances. The test
relies on transgenic embryos bearing a genetic construct, where Green Fluorescent Protein expression
is controlled by THs. In the transgenic embryos, the level of fluorescence reflects the activity of the
TH system. The XETA protocol in its present form has been published as an OECD test guideline
(TG) 248 [13]. Robotisation will allow us to decrease the cost of each test and to increase the rate of
substances screened to medium throughput.
We will evaluate all new test methods in terms of OECD principles of test method validation
and in terms of entry into the European Centre for the Validation of Alternative Methods (ECVAM)
modular process for the submission of test methods for validation. We will analyse the reliability of
the methods (reproducibility of test results within and among laboratories) and their relevance (the
relationship between test outcomes and the effects of a chemical in a target species). This work follows
the Solna Principles, which require a rationale for the test method, establishing a relationship between
the endpoints of a test method and the toxic effect of interest, a formally detailed test protocol (Standard
Operating Procedure), the demonstration of intra-test variability, repeatability and reproducibility,
the demonstration of a test method’s performance by using reference chemicals (positive controls) and
assessments of the new method in relation to existing tests.
2.3.3. Domain 3: Thyroid Hormone System Disruptor Testing in a Multi-Factorial Context and the
Development of Comprehensive Testing Strategies
The impact of new test methods developed in domain 2 of the ATHENA project would be rather
limited if we did not account for multiple intervening factors in the real world that can either exacerbate
or mitigate the effects of chemicals on the TH system. It is also necessary to maximise the impact of
new test methods by integrating them into a comprehensive testing strategy for the protection of the
developing brain from TH system disruptors. This testing strategy should also support regulatory
decision making. The work in domain 3 aims to elaborate on these issues.
We will examine factors that can exacerbate or mitigate the effects of TH system-disrupting
chemicals on foetal brain development. A prominent influence with a potentially significant impact
is iodine deficiency. This is important to understand, as most testing for TH system disruption is
conducted in iodine-rich conditions that are of limited relevance to the iodine-deficient environments
often encountered in human populations. The inhibition of iodotyrosine dehalogenase (IYD) will
be of particular interest, as this enzyme has the capacity to recycle iodide from side products of TH
synthesis. We will also analyse how chemicals that interfere with other hormone systems can modulate
the sensitivity of test organisms to TH system disruptors. Considering that thyroid hypofunction is
especially prevalent in women, the estrogen sex steroid system deserves particular attention.
We will develop testing strategies based on Adverse Outcome Pathways (AOP) for TH system
disruption. This effort will combine existing test methods with the novel methods developed in
ATHENA and integrate these into a coherent testing strategy. Our approach will define a sequence of
test methods to be used for the evaluation of chemicals for their TH system-disrupting properties and
will elaborate upon decision points that specify further testing needs, depending on the outcome of
entry point tests. To put the strategy on a sound footing, we will link it with ongoing AOP development
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activities at the OECD level and extend this to devise a network of quantitative AOP for the TH system.
This will enable us to define which elements of the TH system, when disrupted, will have the greatest
impact on TH insufficiency or hyperfunction and therefore should be targeted through effective testing.
We will develop a workflow that is as parsimonious as possible in terms of resource use, but at the
same time extensive enough so that we can reliably identify thyroid disruptors. We will align the
testing strategy with regulatory needs for the identification of TH system disruptors, as specified by
EU criteria for endocrine disruptors. It is important to define the level of evidence needed to designate
a chemical as a TH system disruptor and establish conditions when further testing can be waived.
We will demonstrate the functionality and practical applicability of the strategy by examination of a
test set of known active and inactive chemicals.
2.3.4. Enhanced International Collaboration, Development of International Strategies for TH System
Disruptor Identification and Regulation
To further enhance the impact of our test method developments, we will progress concepts for
enhanced international collaboration and development in the area of TH system disruptor identification
and regulation.
We will compare international approaches for the regulatory screening, testing and assessment of
substances for thyroid-disrupting properties within the EU and among relevant international trading
partners, including the USA, Canada, China, Japan, South Africa and Australia. We will first update
an existing inventory of completed and ongoing activities related to the screening, priority setting,
testing and assessment of chemicals for their endocrine-disrupting properties [1], in as far as this is
relevant to thyroid disruptors. A previous deep analysis of differences and commonalities in screening,
testing and regulation for TH system disruptors in different EU and non-EU legalities [14] has shown
considerable inconsistencies in terms of toxicity values and assessment factors used for endocrine
disruptor standard setting. Building on this analysis, we will map out a strategy for international
harmonisation that considers the diversity of protection goals enshrined in the body of law of EU and
non-EU legalities.
3. Discussion
The deficiencies of current test guidelines in the OECD Conceptual Framework for endocrine
disruptors are well recognised. The absence of sensitive parameters for the detection of downstream
adverse effects diagnostic of TH system disruption on the developing brain is a major gap in these
guidelines and is likely to hamper the reliable detection of chemicals as endocrine disruptors. Detailed
suggestions for improving test guidelines have been made, especially regarding the inclusion of
endpoints for the identification of adverse effects on brain development and brain morphology [1].
The ATHENA project responds to these suggestions and recommendations and it is hoped that
the ATHENA partnership will achieve significant improvements upon completion of the project.
Three EU chemical regulations are relevant to chemicals that can disrupt the TH system:
Commission Regulation (EU) 2018/605136, an amendment of the Plant Protection Products Regulation
and Commission, and Delegated Regulation (EU) 2017/210072 which addresses the Biocidal Products
Regulation (EU) No 528/201252. Both these regulations define scientific criteria for the determination of
the endocrine-disrupting properties of plant protection products and biocides, respectively. According
to these criteria, endocrine disruptors are substances that:
• Show adverse effects in an intact organism or its progeny, which is a change in the morphology,
physiology, growth, development, reproduction or life span of an organism, system or
(sub)population that results in an impairment of functional capacity, an impairment of the
capacity to compensate for additional stress or an increase in susceptibility to other influences;
• Have an endocrine mode of action (MOA), i.e., alter the function(s) of the endocrine system;
• Exhibit adverse effects because of an endocrine MOA.
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The third relevant regulation, the European Regulation REACH (EC 1907/2006), defines endocrine
disruptors, including TH system disruptors, as substances of very high concern (SVHC) if they induce
effects on human health that give rise to a level of concern similar to those of carcinogens, mutagens
and reproductive toxicants (CMR) or persistent, bioaccumulative or toxic (PBT) or very persistent and
very bioaccumulative chemicals (vPvB).
The challenge for ATHENA is to operationalise the scientific criteria for identifying endocrine
disruptors into test outcomes relevant to TH system disruption. This will take time. In the interim,
it is necessary to make regulatory decisions based on the inadequate data. The European Food Safety
Authority (EFSA) and the European Chemicals Agency (ECHA) have developed guidance for the
application of the endocrine disruptor criteria based on the outcomes of currently available tests [15].
This guidance document proposes the following approaches for the interpretation of data from animal
studies in the context of identifying chemicals that disrupt the TH system:
• Substances inducing histopathological changes in the thyroid (focal hyperplasia and/or neoplasia),
with or without changes in the circulating levels of TH, are regarded as posing a hazard for
human TH insufficiency in adults, as well as the pre- and post-natal neurological development
of offspring;
• Substances that alter circulating levels of T3 and/or T4 without histopathological findings are also
seen as presenting a potential concern for neurodevelopment;
• In the absence of substance-specific data which provide proof of the contrary, humans and rodents
are considered equally sensitive to TH system disruption (including cases where liver enzyme
induction is responsible for increased TH clearance).
This guidance reflects the uncertainty about how TH system disruption can be appropriately
identified in the face of a lack of relevant testing methods. Upon completion of the ATHENA project,
we will be able to place the identification of TH system disruptors on a sound footing.
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